At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IONS Ionis Pharmaceuticals
Pre-Market Trading 12-23 07:56:56 EST
35.63
+0.04
+0.11%
盘前36.00
+0.37+1.04%
04:05 EST
High36.40Low35.05Vol4.06M
Open35.86D1 Closing35.59Amplitude3.79%
Mkt Cap5.63BTradable Cap5.58BTotal Shares157.90M
T/O145.19MT/O Rate2.59%Tradable Shares156.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)
TIPRANKS  ·  17:40
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)
U.S. RESEARCH ROUNDUP-Hershey, Paychex, Revvity
Reuters  ·  15:07
U.S. RESEARCH ROUNDUP-Hershey, Paychex, Revvity
BUZZ-U.S. STOCKS ON THE MOVE-Spire, Copper miners, Abercrombie & Fitch
Reuters  ·  12-21 02:41
BUZZ-U.S. STOCKS ON THE MOVE-Spire, Copper miners, Abercrombie & Fitch
Intellia Crashes 60% in a Year: How Should You Play the Stock?
Zacks  ·  12-21 01:57
Intellia Crashes 60% in a Year: How Should You Play the Stock?
Ionis FDA approval a positive for Arrowhead, says H.C. Wainwright
TIPRANKS  ·  12-20 22:26
Ionis FDA approval a positive for Arrowhead, says H.C. Wainwright
BUZZ-U.S. STOCKS ON THE MOVE-Humacyte, Ionis Pharmaceuticals, Emeren Group
Reuters  ·  12-20 22:12
BUZZ-U.S. STOCKS ON THE MOVE-Humacyte, Ionis Pharmaceuticals, Emeren Group
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
Zacks  ·  12-20 21:03
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
Benzinga  ·  12-20
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
BUZZ-U.S. STOCKS ON THE MOVE-FedEx, Eli Lilly, Aadi Bioscience
Reuters  ·  12-20
BUZZ-U.S. STOCKS ON THE MOVE-FedEx, Eli Lilly, Aadi Bioscience
BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug
Reuters  ·  12-20
BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug
Ionis Pharmaceuticals reports FDA approval of Tryngolza
TIPRANKS  ·  12-20
Ionis Pharmaceuticals reports FDA approval of Tryngolza
Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug
MT Newswires Live  ·  12-20
Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug
Ionis Pharmaceuticals trading resumes
TIPRANKS  ·  12-20
Ionis Pharmaceuticals trading resumes
BRIEF-Tryngolza (Olezarsen) Approved In U.S. As First-Ever Treatment For Adults Living With Familial Chylomicronemia Syndrome As An Adjunct To Diet
Reuters  ·  12-20
BRIEF-Tryngolza (Olezarsen) Approved In U.S. As First-Ever Treatment For Adults Living With Familial Chylomicronemia Syndrome As An Adjunct To Diet
Tryngolza™ (Olezarsen) Approved in U.S. as First-Ever Treatment for Adults Living With Familial Chylomicronemia Syndrome as an Adjunct to Diet
THOMSON REUTERS  ·  12-20
Tryngolza™ (Olezarsen) Approved in U.S. as First-Ever Treatment for Adults Living With Familial Chylomicronemia Syndrome as an Adjunct to Diet
Ionis Pharmaceuticals Inc - Tryngolza to Be Available in U.S. Before Year End
THOMSON REUTERS  ·  12-20
Ionis Pharmaceuticals Inc - Tryngolza to Be Available in U.S. Before Year End
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
PR Newswire  ·  12-20
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
BRIEF-FDA Approves Ionis Pharmaceuticals' Olezarsen For Familial Chylomicronemia Syndrome- Website
Reuters  ·  12-20
BRIEF-FDA Approves Ionis Pharmaceuticals' Olezarsen For Familial Chylomicronemia Syndrome- Website
US FDA approves Ionis Pharma's genetic disorder drug
Reuters  ·  12-20
US FDA approves Ionis Pharma's genetic disorder drug
FDA Approves Ionis Pharmaceuticals' Olezarsen for Familial Chylomicronemia Syndrome- Website
THOMSON REUTERS  ·  12-20
FDA Approves Ionis Pharmaceuticals' Olezarsen for Familial Chylomicronemia Syndrome- Website

Introduction

Company Name.
Ionis Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
Issue price:
--